Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:11 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Active Biotech Q2 2024 - Both Myelofibrosis Studies Soon Recruiting

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Active Biotech Q2 2024 - Both Myelofibrosis Studies Soon Recruiting

2024-08-23 08:27:00

Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presented by NeoTX in the quarter, with inconclusive results. The US study in myelofibrosis is ready to recruit the first patient, while the European study is estimated to be ready to begin recruitment in Q3.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/